(Q33420207)

26 July 2017

1 reference

title

Thrombopoiesis-stimulating agents and myelodysplastic syndromes (English)

1 reference

26 July 2017

Charlotte K Brierley

1

0 references

author name string

David P Steensma

series ordinal

2

1 reference

26 July 2017

language of work or name

English

0 references

publication date

6 February 2015

1 reference

British Journal of Haematology

26 July 2017

published in

1 reference

26 July 2017

volume

169

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

309-323

1 reference

Evaluating the prognosis of patients with myelodysplastic syndromes

26 July 2017

cites work

1 reference

Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl.

21 January 2018

1 reference

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia

21 January 2018

1 reference

The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

21 January 2018

1 reference

Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases

21 January 2018

1 reference

c-mpl expression in hematologic disorders

21 January 2018

1 reference

AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.

21 January 2018

1 reference

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura

21 January 2018

1 reference

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia

21 January 2018

1 reference

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

21 January 2018

1 reference

Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia

21 January 2018

1 reference

Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine

21 January 2018

1 reference

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma

21 January 2018

1 reference

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

21 January 2018

1 reference

The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl

21 January 2018

1 reference

Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist

21 January 2018

1 reference

Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment

21 January 2018

1 reference

How we treat lower-risk myelodysplastic syndromes

21 January 2018

1 reference

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

21 January 2018

1 reference

Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia.

21 January 2018

1 reference

A prognostic score for patients with lower risk myelodysplastic syndrome

21 January 2018

1 reference

Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials

21 January 2018

1 reference

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

21 January 2018

1 reference

Platelet associated IgG may be related with thrombocytopenia in patients with myelodysplastic syndromes

21 January 2018

1 reference

Defective platelet aggregation in myelodysplastic syndromes

21 January 2018

1 reference

Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome

21 January 2018

1 reference

Revised international prognostic scoring system for myelodysplastic syndromes

21 January 2018

1 reference

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine

21 January 2018

1 reference

Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies.

21 January 2018

1 reference

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

21 January 2018

1 reference

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

21 January 2018

1 reference

Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death

21 January 2018

1 reference

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist

21 January 2018

1 reference

Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes

21 January 2018

1 reference

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

21 January 2018

1 reference

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

21 January 2018

1 reference

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia

21 January 2018

1 reference

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

21 January 2018

1 reference

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes

21 January 2018

1 reference

Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin

21 January 2018

1 reference

Milestones in understanding platelet production: a historical overview

21 January 2018

1 reference

Recombinant human thrombopoietin: basic biology and evaluation of clinical studies

21 January 2018

1 reference

The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production

21 January 2018

1 reference

Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres

21 January 2018

1 reference

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

21 January 2018

1 reference

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim

21 January 2018

1 reference

Romiplostim or standard of care in patients with immune thrombocytopenia

21 January 2018

1 reference

21 January 2018

1 reference

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

21 January 2018

1 reference

Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.

21 January 2018

1 reference

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome

21 January 2018

1 reference

Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome

21 January 2018

1 reference

Platelet transfusions: the problem of refractoriness

21 January 2018

1 reference

Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes

21 January 2018

1 reference

Eltrombopag and improved hematopoiesis in refractory aplastic anemia

21 January 2018

1 reference

Romiplostim for management of chemotherapy-induced thrombocytopenia

21 January 2018

1 reference

Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?

21 January 2018

1 reference

Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.

21 January 2018

1 reference

Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms

21 January 2018

1 reference

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

Phase II study of roquinimex in myelodysplastic syndrome

21 January 2018

1 reference

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study

21 January 2018

1 reference

Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database

21 January 2018

1 reference

Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.

21 January 2018

1 reference

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

21 January 2018

1 reference

Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes

21 January 2018

1 reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

Molecular cloning and chromosomal localization of the human thrombopoietin gene.

21 January 2018

1 reference

A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors

21 January 2018

1 reference

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine

21 January 2018

1 reference

Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes

21 January 2018

1 reference

21 January 2018

1 reference

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

21 January 2018

1 reference

Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases

21 January 2018

1 reference

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.13285

1 reference

26 July 2017

1 reference